Diligence memo · auto-generated · as of July 2, 2026

Salutaris Medical Devices Inc

Salutaris Medical Devices Inc looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Salutaris Medical Devices Inc operates in Biotechnology, based in Tucson.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Salutaris Medical Devices Inc has raised $5.4M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $2.1M on 2009-02-26.

Most recent recorded round closed around 2018-02-12.

Valuation (modeled)modeled

Provath models Salutaris Medical Devices Inc at approximately $6.4M (range $104K–$50M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.09× the median modeled value of Seed Biotechnology companies in 2016–2018 (175 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 11 months.

Last raise 8.4 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 2.1× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 46% of Biotechnology peers (4293 compared).

Modeled value ranks above 13% of those peers.

Closest niche peers: Mimedx Group, Inc., Kenjockety Biotechnology, LLC, Helocyte, Inc., CytoDel, INC., Finch Therapeutics, Inc..

Peoplefiled

10 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.